Af­ter pulling Blenrep from US mar­kets, GSK plots a come­back with PhI­II mul­ti­ple myelo­ma tri­al suc­cess

GSK an­nounced Mon­day that its mul­ti­ple myelo­ma drug Blenrep suc­ceed­ed in a Phase III tri­al as part of a sec­ond-line com­bi­na­tion treat­ment for pa­tients whose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.